Estefanía Martino‐Echarri

Author

Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research

Also Known As

Estefania Martino-Echarri, Estefanía Martino-Echarri, Estefanía Martino‐Echarri

Publications

497

Citations

H-Index

Concepts

All Affiliations

Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research The University of Sydney Westmead Institute for Medical Research Queen Mary University of London Westmead Hospital

About

Estefanía Martino‐Echarri is an author at Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	388
2	Cell Biology	7	7	388
3	Natural Sciences	2	2	73
4	Biochemistry	1	1	30
5	Chemical Biology	1	1	30

Estefanía Martino‐Echarri

Publications

488

Citations

H-Index

Page 1

	Year	Citations
Tumour angiogenesis is reduced in the Tc1 mouse model of Down’s syndrome Louise E. Reynolds, Alan R. Watson, Marianne Baker, Nature AngiogenesisTc1 Mouse ModelPathologyCancer Cell BiologyTumor Suppressor	2010	134
Rac1 augments Wnt signaling by stimulating β-catenin–lymphoid enhancer factor-1 complex assembly independent of β-catenin nuclear import Cara Jamieson, Christina Lui, Mariana Brocardo, Journal of Cell Science Transcriptional RegulationSystems BiologySignal TransductionSignaling PathwayCell Regulation	2015	66
ADAMTS1 Contributes to the Acquisition of an Endothelial-like Phenotype in Plastic Tumor Cells Carmen Casal, Antoni X. Torres‐Collado, María del Carmen Plaza‐Calonge, Cancer Research Biological MicroenvironmentsPlastic Tumor CellsCancer BiologyTumor BiologyAngiogenesis	2010	52
Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells Sharon M. Sagnella, Lu Yang, Gemma E. Stubbs, Cancer Cell Cell-based Drug DeliveryNanomedicineTumor ImmunologyPolymer-drug ConjugateImmunology	2020	52
Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogen‐1 and nidogen‐2 Estefanía Martino‐Echarri, Rubén Fernández‐Rodríguez, Francisco Javier Rodríguez‐Baena, International Journal of Cancer PathologyHuman Breast CarcinomaCancer BiologyTumor BiologyAngiogenesis	2013	43
Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapy Estefanía Martino‐Echarri, Beric R. Henderson, Mariana Brocardo Oncotarget	2014	38
Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta Estefanía Martino‐Echarri, Mariana Brocardo, Kate Mills, PLoS ONE Drive AssemblyPathologyAxin PunctaChemical BiologyCancer Biology	2016	30
ADAMTS1 protease is required for a balanced immune cell repertoire and tumour inflammatory response Francisco Javier Rodríguez‐Baena, Silvia Redondo-García, Carlos Peris-Torres, Scientific Reports	2018	27
Stroma-derived but not tumor ADAMTS1 is a main driver of tumor growth and metastasis Rubén Fernández‐Rodríguez, Francisco Javier Rodríguez‐Baena, Estefanía Martino‐Echarri, Oncotarget	2016	21
Relevance of IGFBP2 proteolysis in glioma and contribution of the extracellular protease ADAMTS1 Estefanía Martino‐Echarri, Rubén Fernández‐Rodríguez, Joan Josep Bech‐Serra, Oncotarget	2014	14

Page 1